Last reviewed · How we verify

tacrolimus, ATG — Competitive Intelligence Brief

tacrolimus, ATG (tacrolimus, ATG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor and polyclonal antithymocyte antibody. Area: Immunology.

marketed Calcineurin inhibitor and polyclonal antithymocyte antibody Calcineurin (tacrolimus); T-cell surface antigens including CD2, CD3, CD4, CD8, CD25 (ATG) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

tacrolimus, ATG (tacrolimus, ATG) — University Hospital, Toulouse. Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation, while ATG (antithymocyte globulin) is a polyclonal antibody that depletes T lymphocytes, together providing potent immunosuppression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
tacrolimus, ATG TARGET tacrolimus, ATG University Hospital, Toulouse marketed Calcineurin inhibitor and polyclonal antithymocyte antibody Calcineurin (tacrolimus); T-cell surface antigens including CD2, CD3, CD4, CD8, CD25 (ATG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcineurin inhibitor and polyclonal antithymocyte antibody class)

  1. University Hospital, Toulouse · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tacrolimus, ATG — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-atg. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: